Abstract

Thalassemia is a blood inherited disorder caused due to defective hemoglobin synthesis in the red blood cells in the body. It is one of the common genetic disorder, from which nearly 200 million people globally [1] are being affected either as a thalassemia minor or major or sometimes as a carrier-whom only carry genes not affected by symptoms. Most thalassemia carrier are not aware of their carrier status [2], which remains a great threat to transmit the disease. The nature and limited treatment options for the disease imposes a heavy psychosocial burden on patients and their families [3]. Recent advances in the diagnostics and preventive medicine of genetic disorders particularly in thalassemia have improved patient survival through the options like blood transfusion, chelation therapy, and gene therapy [4]. Similarly, patients’ well-being has also increased significantly in accordance with technological advancements leading to increased function of their entire family [1,5], having their day today activities normal.